06-005 · EVIDENCE A · LOW-RISK READING

Don’t expect glucosamine/chondroitin to treat knee osteoarthritis

不要指望氨糖(葡萄糖胺)/软骨素治膝关节炎

Source cost

Roughly 2–5 RMB per day, or 700–1800 RMB per year.

Source return

In a major clinical trial for knee osteoarthritis over 24 weeks, dummy pills alone produced pain relief in 60.1% of patients. Adding glucosamine or chondroitin provided no statistically meaningful improvement beyond that effect. Spending 700–1800 RMB yearly essentially buys you the same expectation effect seen in 60% of people without active ingredients.

Evidence grade

A

THE LOW-ROI DETOURSatire, not advice

Move “Don’t expect glucosamine/chondroitin to treat knee osteoarthritis” to Future Me's calendar

The excuse

The routine already works until the day the source says it may not.

What feels good now

Today I keep a few minutes and avoid interrupting my default routine.

What the source says

The source summarizes the return this way: “In a major clinical trial for knee osteoarthritis over 24 weeks, dummy pills alone produced pain relief in 60.1% of patients. Adding glucosamine or chondroitin provided no statistically meaningful improvement beyond that effect. Spending 700–1800 RMB yearly essentially buys you the same expectation effect seen in 60% of people without active ingredients.” Evidence grade A. The original states the population, caveats, and sources; this is not a personal forecast.

THE ENGLISH EDITION

Original recommendation and evidence

Source commit a994b6a0c905

5. Don’t expect glucosamine/chondroitin to treat knee osteoarthritis

Cost: Roughly 2–5 RMB per day, or 700–1800 RMB per year.

In plain terms: In a major clinical trial for knee osteoarthritis over 24 weeks, dummy pills alone produced pain relief in 60.1% of patients. Adding glucosamine or chondroitin provided no statistically meaningful improvement beyond that effect. Spending 700–1800 RMB yearly essentially buys you the same expectation effect seen in 60% of people without active ingredients.

Benefit: As noted above, glucosamine and chondroitin showed minimal benefits compared to placebo. The real active drug in the trial, celecoxib, produced a 10.0 percentage point improvement (P=0.008). The perceived value of glucosamine/chondroitin stems from their “cartilage-repair” reputation and the fact that placebo alone helped 60% of patients.

Evidence grade: A

Sources: Clegg DO et al. (2006). Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. NEJM. <https://doi.org/10.1056/NEJMoa052771>

Notes: Controversy: Among participants with severe baseline pain, those taking both supplements saw a 79.2% pain-reduction rate versus 54.3% in the placebo group (P=0.002). However, researchers note this finding was derived post-hoc and should be viewed as a preliminary clue rather than a definitive conclusion. Proven treatments for knee osteoarthritis include weight loss and muscle-strengthening exercises — see Section 2.

Read the complete Chinese source and notes

5. 不要指望氨糖(葡萄糖胺)/软骨素治膝关节炎

成本: 一天约 2 到 5 元,一年 700 到 1800 元。

说人话: 膝盖有骨关节炎的人吃 24 周假药,也有六成说没那么疼了。吃氨糖或软骨素的人只比这多出四五个百分点,小到可能只是碰巧。一年花七百到一千八,买到的基本就是那六成的心理作用。

收益: GAIT 试验找了 1,583 名膝骨关节炎患者,吃 24 周。吃安慰剂(假药)的人里,也有 60.1% 说疼痛缓解了。氨糖只比它高 3.9 个百分点(P=0.30)。软骨素高 5.3 个百分点(P=0.17)。两样一起吃高 6.5 个百分点(P=0.09)。这几个差距都太小,不能排除只是碰巧。同一个试验里用来做对照的真药塞来昔布,高 10.0 个百分点(P=0.008)。它看起来划算,是因为「补软骨的原料」听起来正好对症,而且光吃假药就有六成人说有效

证据等级: A

来源: Clegg DO et al. (2006). Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. NEJM. <https://doi.org/10.1056/NEJMoa052771>

备注: 争议:同一个试验里,一开始就疼得厉害的那批人,两样一起吃的有效比例是 79.2%,对照组 54.3%(P=0.002)。但作者说这是事后从数据里翻出来的,只能当线索,不能当结论。膝关节炎真正有证据的做法是减重和练肌肉,见第 2 节

Author's scope notes: 争议:同一个试验里,一开始就疼得厉害的那批人,两样一起吃的有效比例是 79.2%,对照组 54.3%(P=0.002)。但作者说这是事后从数据里翻出来的,只能当线索,不能当结论。膝关节炎真正有证据的做法是减重和练肌肉,见第 2 节

YOUR PRIVATE LIST

Choose what to do with this idea

Related source entries

Original content by eternity4719 under CC BY 4.0. English translation is credited in the source notes. HowToLiveWorse adds a clearly labeled satirical response.

Full source and adaptation notes